ICU Medical (NASDAQ:ICUI) VP Sells $982,264.61 in Stock

ICU Medical, Inc. (NASDAQ:ICUI) VP Daniel Woolson sold 5,417 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $181.33, for a total value of $982,264.61. Following the transaction, the vice president owned 17,062 shares in the company, valued at $3,093,852.46. This represents a 24.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

ICU Medical Trading Down 0.1%

ICUI opened at $182.98 on Friday. The company has a quick ratio of 1.21, a current ratio of 2.43 and a debt-to-equity ratio of 0.56. ICU Medical, Inc. has a 52 week low of $112.50 and a 52 week high of $192.85. The business’s 50 day moving average is $156.56 and its two-hundred day moving average is $141.96. The firm has a market cap of $4.57 billion, a price-to-earnings ratio of 155.07, a price-to-earnings-growth ratio of 2.56 and a beta of 0.74.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.46. The business had revenue of $547.88 million during the quarter, compared to the consensus estimate of $533.44 million. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.The company’s revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the company earned $2.10 earnings per share. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, research analysts predict that ICU Medical, Inc. will post 6.51 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ICUI. Jefferies Financial Group upgraded shares of ICU Medical to a “strong-buy” rating in a research note on Thursday, May 7th. KeyCorp lifted their price objective on shares of ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a research note on Tuesday, July 21st. Wall Street Zen raised shares of ICU Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Sanford C. Bernstein downgraded shares of ICU Medical to a “market perform” rating in a research note on Monday, June 15th. Finally, BTIG Research raised their price target on ICU Medical from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $192.80.

Hedge Funds Weigh In On ICU Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of ICUI. BlackRock Inc. acquired a new stake in shares of ICU Medical in the 2nd quarter worth $550,250,000. Jupiter Topco LLC purchased a new stake in shares of ICU Medical in the second quarter valued at about $407,786,000. Vanguard Group Inc. boosted its holdings in shares of ICU Medical by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 2,714,746 shares of the medical instruments supplier’s stock valued at $387,313,000 after acquiring an additional 89,755 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of ICU Medical by 3.9% during the first quarter. Janus Henderson Group PLC now owns 2,676,012 shares of the medical instruments supplier’s stock worth $345,607,000 after acquiring an additional 99,256 shares during the period. Finally, Millennium Management LLC increased its stake in shares of ICU Medical by 173.4% during the third quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock worth $130,638,000 after acquiring an additional 690,694 shares during the period. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.